Key result
High stromal POSTN expression in colorectal cancer was an independent prognostic indicator of poor 5-year cancer-specific survival (HR 1.50) and progression-free survival (HR 1.38).
Why the study?
Does high stromal POSTN expression predict poor survival in patients with colorectal cancer?
Cohort (n=1,125)
No
Does high stromal POSTN expression predict poor survival in patients with colorectal cancer?
Hazard Ratio: 1.5 (95% CI 1.13–2)
p-value: p=0.006
High stromal POSTN expression is an independent predictor of poor 5-year cancer-specific and progression-free survival in patients with colorectal cancer.
BACKGROUND: Tumor microenvironment has recently drawn attention in that it is related with tumor prognosis. Cancer-associated fibroblast also plays a critical role in cancer invasiveness and progression in colorectal cancers. Periostin (POSTN), originally identified to be expressed in osteoblasts and osteoblast-derived cells, is expressed in cancer-associated fibroblasts in several tissue types of cancer. Recent studies suggest an association between stromal overexpression of POSTN and poor prognosis of cancer patients. METHODS: We analyzed colorectal cancer cases for their expression status of POSTN in tumor stroma using immunohistochemistry and correlated the expression status with clinicopathological and molecular features. RESULTS: High level of POSTN expression in tumor stroma was closely associated with tumor location in proximal colon, infiltrative growth pattern, undifferentiated histology, tumor budding, luminal necrosis, and higher TNM stage. High expression status of POSTN in tumor stroma was found to be an independent prognostic parameter implicating poor 5-year cancer-specific survival and 5-year progression-free survival. CONCLUSIONS: Our findings suggest that POSTN overexpression in tumor stroma of colorectal cancers could be a possible candidate marker for predicting poor prognosis in patients with colorectal cancers.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2017) conducted a cohort in Colorectal cancer (n=1,125). High stromal POSTN expression vs. Low stromal POSTN expression was evaluated on 5-year cancer-specific survival (HR 1.50, 95% CI 1.13-2.00, p=0.006). High stromal POSTN expression in colorectal cancer was an independent prognostic indicator of poor 5-year cancer-specific survival (HR 1.50) and progression-free survival (HR 1.38).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: